Laboratoires Medidom

Medidom is a Swiss pharmaceutical company specializing in the research, development, and commercialization of innovative therapies for rheumatology and ophthalmology. Founded in 1977 and headquartered in Geneva, the company is best known for developing Hyalgan, a leading intra-articular sodium hyaluronate treatment for osteoarthritis. It also developed Diacerein, an oral anti-inflammatory drug that specifically targets interleukin-1 to treat degenerative joint diseases. Medidom operates primarily through a licensing and intellectual property model, partnering with global pharmaceutical firms to distribute its proprietary products worldwide. The company maintains a strong focus on improving patient outcomes in chronic conditions through the development of viscosupplementation and specialized small molecules. As a private entity, it has established a significant global footprint through strategic alliances and a robust portfolio of patents in the field of connective tissue disorders.